Our Recombinant Human and Mouse IL-18/IL-1F4 proteins are manufactured in-house and offer a much better value than the closest competitor. Compare quantity, units, purity, endotoxin levels, and dollars per unit for yourself using the table below.
IL-18/IL-1F4 Protein Benefits Include:
- Equivalent high activity levels as the leading competitor
- Increased stability compared to the leading competitor
- Superior purity
| R&D Systems (Catalog # 9124-IL) |
Leading Competitor | R&D Systems (Catalog # 9139-IL) |
Leading Competitor | |||||||
| Species | Human | Human | Mouse | Mouse | ||||||
| Source | E. coli | E. coli | E. coli | E. coli | ||||||
| Mass per vial | 10 µg | 50 µg | 500 µg | 25 µg | 200 µg | 10 µg | 50 µg | 500 µg | 25 µg | 200 µg |
| Activity (ED50) | 1.5-9 ng/mL | 1.5-9 ng/mL | 0.06-0.36 ng/mL | 0.06-0.36 ng/mL | ||||||
| Endotoxin specification |
<0.1 per 1 µg of the protein by the LAL method. | <1.0 per 1 µg of the protein by the LAL method. | <0.1 per 1 µg of the protein by the LAL method. | <1.0 per 1 µg of the protein by the LAL method. | ||||||
| Purity | >95% by SDS-PAGE (Silver Staining and Coomassie) | >90% by SDS-PAGE (Coomassie) | >90% by SDS-PAGE (Silver Staining and Coomassie) | >90& by SDS-PAGE (Coomassie) | ||||||
| Price | $169 | $289 | $1,229 | $349 | $1,439 | $169 | $289 | $1,229 | $349 | $1,439 |
| Dollars per µg | $16.90 | $5.78 | $2.46 | $13.96 | $7.20 | $16.90 | $5.78 | $2.46 | $13.96 | $7.20 |
Get the most superior IL-18 on the market. |
|
| Buy rhIL-18 Now | Buy rmIL-18 Now |
Compare IL-18/IL-1F4 Protein Bioactivity
 |
 |
A) Recombinant Human IL-18 (Catalog # 9124-IL) induces IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells. The ED50 for this effect is typically 1.5-9 ng/mL. IFN-gamma was measured in the cell culture supernatant using the Human IFN-gamma Quantikine® ELISA kit (Catalog # DIF50). B) Recombinant Mouse IL-18/IL1F4 (Catalog # 9139-IL) induces IFN-gamma secretion by activated mouse T cells. The ED50 for this effect is typically 0.06-0.36 ng/mL. IFN-gamma was measured in the cell culture supernatant using the Mouse IFN-gamma Quantikine® ELISA kit (Catalog # MIF00). The combination of high activity and competitive pricing makes R&D Systems® IL-18 proteins the better choice.
Increased IL-18/IL-1F4 Protein Stability
 |
Recombinant Mouse IL-18/IL-1F4 (Catalog # 9139-IL) induces IFN-gamma secretion by activated mouse T cells. Serial dilutions of either R&D Systems® IL-18 or IL-18 from a leading competitor (vials freshly reconstituted or vials stored 1 month at 4 °C after reconstitution) were incubated overnight with activated mouse T cells. IFN-gamma was measured in the cell culture supernatant using the Mouse IFN-gamma Quantikine® ELISA kit (Catalog # MIF00).
Our IL-18/IL-1F4 Proteins Provide Superior Purity
 Recombinant Human IL-18/IL-1F4(ng/mL) |
 Recombinant Mouse IL-18/IL-18-1F4(ng/mL) |
1 µg/lane of Recombinant Human IL-18/IL-1F4 (Catalog # 9124-IL) (A) and Recombinant Mouse IL-18/IL-1F4 (Catalog # 9139-IL) (B) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing a single band at 18 kDa.
Background Information for IL-18
Interleukin-18 (IL-18), a member of the IL-1 family of pro-inflammatory cytokines, is produced by various hematopoietic and nonhematopoietic cells, including dendritic cells, macrophages, microglial cells, keratinocytes, and epithelial cells (1, 2). IL-18 is expressed as a 24 kDa inactive precursor (pro-IL-18) and processed by the intracellular cysteine protease caspase-1 into a 17.2 kDa active mature molecule and released from cells (3, 4). IL-18 plays important roles regulating both innate and acquired immune responses through its effects on natural killer cells, monocytes, dendritic cells, T cells, and B cells. It is a target for immune intervention in infectious diseases, autoimmune diseases, and cancers (5-7).
Get the most superior IL-18 on the market. |
|
| Buy rhIL-18 Now | Buy rmIL-18 Now |
References
- Okamura, H. et al. (1995) Nature 378:88.
- Gracie, J.A. et al. (2003) J. Leukoc. Biol. 73:213.
- Dinarello, C.A. et al. (2013). Front. Immunol. 4:289.
- Wei, H. et al. (2014) FEBS Lett. 558:3838.
- Wawrocki, S. et al. (2016) Acta. Biochim. Pol. 63:59.
- Kanai, T. et al. (2013) Curr. Drug Targets 14:1392.
- Fabbi, M. et al. (2015) J. Leukoc. Biol. 97:665.